Topical application of a film-forming emulgel dressing that controls the release of stratifin and acetylsalicylic acid and improves/prevents hypertrophic scarring

Wound Repair Regen. 2013 Jan-Feb;21(1):55-65. doi: 10.1111/j.1524-475X.2012.00857.x. Epub 2012 Nov 5.


Here, we evaluate the efficacy of an emulgel dressing to control the release of an antifibrogenic factor, stratifin (SFN), along with an anti-inflammatory drug, acetylsalicylic acid (ASA), to be used as a wound dressing with hypertrophic scar reducing features. Emulgel dressings were prepared by dispersing positively charged submicron vesicles in carboxymethyl cellulose gel. Release kinetics of SFN/ASA and toxicity for primary skin cells were assessed in vitro. Antifibrogenic efficacy of medicated emulgel dressings was tested on a rabbit ear fibrotic model. Following topical application on the wounds, emulgels formed an occlusive film and controlled the release of SFN and ASA for 7 and 24 hours, respectively. Wounds treated with SFN/ASA-containing emulgel dressings showed an 80% reduction in scar elevation compared with untreated controls. Topical formulations were nontoxic for cultured human keratinocytes and fibroblasts. Inflammation was significantly controlled in treated wounds, as shown by a reduced number of infiltrated CD3(+) T cells (p < 0.001) and macrophages. SFN/ASA-treated wounds showed a significantly higher (p < 0.001) expression of matrix metalloproteinase-1, resulting in reduced collagen deposition and less scarring. Film-forming emulgel dressings that control the release of antifibrogenic and anti-inflammatory factors provide an excellent treatment option for postburn hypertrophic scar management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 14-3-3 Proteins / pharmacology*
  • Administration, Cutaneous
  • Animals
  • Aspirin / administration & dosage
  • Aspirin / pharmacology*
  • Bandages
  • Biomarkers, Tumor / pharmacology*
  • Cicatrix, Hypertrophic / drug therapy*
  • Cicatrix, Hypertrophic / pathology
  • Cicatrix, Hypertrophic / prevention & control
  • Delayed-Action Preparations / pharmacology*
  • Disease Models, Animal
  • Exonucleases / pharmacology*
  • Exoribonucleases
  • Fibroblasts / drug effects
  • Gels / pharmacology*
  • Humans
  • Keratinocytes / drug effects
  • Matrix Metalloproteinase 1 / drug effects
  • Rabbits
  • Wound Healing* / drug effects
  • Wounds and Injuries / drug therapy*
  • Wounds and Injuries / pathology


  • 14-3-3 Proteins
  • Biomarkers, Tumor
  • Delayed-Action Preparations
  • Gels
  • Exonucleases
  • Exoribonucleases
  • SFN protein, human
  • Matrix Metalloproteinase 1
  • Aspirin